Sponsor or institution
Clinical trials and research at European Organisation for Research and Treatment of Cancer - EORTC
As of November 12, 2026, Find a Trial lists 17 clinical trials run by European Organisation for Research and Treatment of Cancer - EORTC that are recruiting, at sites in 30 countries (most in France (14), Spain (13), Belgium (12)). By phase: Phase 3 (7), Phase 2 (3). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 17Clinical trials
- 30Countries
Newest trials
All recruiting trials (17)
-
Radiotherapy for BCG-Unresponsive Bladder CIS
This study tests whether radiation therapy can help people with BCG-unresponsive non-muscle-invasive bladder cancer to delay or avoid bladder removal.
-
Vorasidenib as daily maintenance therapy for adults with IDH‑mutant grade 2–3 astrocytoma
This trial will test whether taking daily vorasidenib after chemoradiotherapy delays tumor progression compared with placebo in adults with IDH‑mutant grade 2 or 3 astrocytoma.
-
Radiopharmaceutical treatment for advanced kidney cancer using 177Lu-PSMA-617
This study tests whether 177Lu-PSMA-617 can help adults with metastatic clear cell renal cell carcinoma that has progressed after immunotherapy and a VEGFR-TKI.
-
Single‑fraction versus multiple‑fraction SBRT for treating limited metastases (SPRINT)
This trial will test whether a single high‑dose SBRT treatment works as safely and effectively as multiple smaller SBRT treatments for people with limited metastases from breast, prostate, lung, or colorectal cancer.
-
Using 177Lu-DOTATATE to treat recurrent meningioma
This study is testing if a new targeted treatment called 177Lu-DOTATATE can help people with recurrent meningioma who haven't had success with regular treatments like surgery and radiation.
-
Using Tebentafusp to prevent recurrence in high-risk ocular melanoma patients
This study is testing if a new treatment called tebentafusp can help prevent the return of high-risk uveal melanoma in patients after their initial treatment.
-
Intermittent hormone suppression with AR pathway inhibitors for metastatic prostate cancer
This trial will test whether planned treatment breaks from continuous androgen‑deprivation plus AR pathway inhibitors work as well as staying on continuous therapy for men with metastatic hormone‑naïve prostate cancer who have very low PSA after 6–12 months of treatment.
-
Combining Lomustine with Reirradiation for Glioblastoma Progression
This study is testing if adding a chemotherapy drug called lomustine to reirradiation can help people with glioblastoma live longer after their cancer has progressed.
-
Pembrolizumab plus targeted stereotactic radiotherapy for oligometastatic head and neck squamous cell carcinoma
This study tests whether adding stereotactic ablative radiotherapy (SABR) to pembrolizumab helps people with oligometastatic squamous cell carcinoma of the head and neck stay progression-free longer.
-
Using elacestrant to treat ER+/HER2- breast cancer patients with ctDNA relapse
This study is testing if a new drug called elacestrant can help women with ER-positive, HER2-negative breast cancer who have had a relapse, compared to their usual treatment.
-
Observational assessment of treatment outcomes for patients with primary brain tumors
This study looks at how well treatments work for people with rare primary brain tumors using new classification guidelines to see if they help doctors group patients better.
-
Comparing brain MRI surveillance to prophylactic cranial irradiation in small cell lung cancer patients
This study is testing if regular brain MRIs alone can help small cell lung cancer patients just as much as a combination of brain MRIs and preventive radiation therapy.
-
Using stereotactic body radiotherapy for patients with rare oligometastatic cancers
This study is testing if adding a special type of targeted radiation therapy to standard treatment can help people with rare cancers that have spread to a few places live longer and feel better.
-
Combining Mogamulizumab with Total Skin Electron Beam Therapy for Skin Lymphoma
This study is testing if combining a new drug called Mogamulizumab with a special type of radiation therapy can help people with advanced skin lymphoma who haven't had success with other treatments.
-
Surgery with or without chemotherapy for high-risk retroperitoneal sarcoma
This study is testing if giving chemotherapy before surgery can help people with high-risk retroperitoneal sarcoma live longer without their cancer coming back.
-
Collecting real-world data on cancer patients treated with radiotherapy in Europe
This study is collecting information from cancer patients receiving radiotherapy in Europe to see how well this treatment works alongside other therapies.
-
Screening cancer patients for better access to clinical trials
This study is trying to see if collecting detailed information and samples from cancer patients can help improve access to clinical trials and enhance cancer treatment.
Quick answers
How many clinical trials run by European Organisation for Research and Treatment of Cancer - EORTC are recruiting right now?
17, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 30 countries. The most sites are in France (14 trials), Spain (13 trials), Belgium (12 trials), Italy (12 trials), Germany (11 trials). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 7, Phase 2: 3. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.